Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Lignende værker

• Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
  af: Motzer, Robert J., et al.
  Udgivet: (2014)
• Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
  af: Knox, J. J., et al.
  Udgivet: (2017)
• Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
  af: Knox, J J, et al.
  Udgivet: (2018)
• 2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma
  af: Collado-Borrell, R, et al.
  Udgivet: (2018)
• Malignant epitheloid angiomyolipoma of the kidney in a child treated with sunitinib, everolimus and axitinib
  af: Citak, Elvan Caglar, et al.
  Udgivet: (2015)